Loading
A phase 1/2 trial of Rituximab, Daratumumab, Aldesleukin in multiple myeloma and hodgkin lymphoma, run by Indapta Therapeutics, INC., now recruiting.
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers is a phase 1/2 interventional study registered as NCT06119685 by Indapta Therapeutics, INC., with 128 participants planned, started 2023-10-25 and due to reach its primary completion in 2025-12-30. Interventions recorded: IDP-023, Rituximab, Daratumumab, Interleukin-2, Cyclophosphamide. Conditions listed: NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aldesleukin (high-dose IL-2), Fludarabine, Cyclophosphamide.
Shares Aldesleukin (high-dose IL-2), Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Aldesleukin (high-dose IL-2), Fludarabine, Cyclophosphamide.
Shares Aldesleukin (high-dose IL-2), Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide, Non-Hodgkin lymphoma (all types).
Shares Aldesleukin (high-dose IL-2), Daratumumab, Multiple myeloma.
Shares Rituximab, Cyclophosphamide, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/